Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Novartis AG — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Novartis AG trades at $149.5 (market cap $271.82B). The key difference: Novartis AG is far larger — about 95× Dyne Therapeutics Inc. Common Stock's market cap, and Novartis AG pays a 3.33% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Novartis AG for 82 Days on average.
| DYN | NVS | |
|---|---|---|
Market Cap | $2.86B | $271.82B |
Volume | 3,341,579 | 1,841,354 |
Sector | Health | Health |
52-Week High | $26.78 | $168.62 |
52-Week Low | $14.60 | $121.80 |
Typical Hold Time | 0 Days | 82 Days |
Enterprise Value | $2.18B | $313.15B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
NVS trades at $146.88, up 2.11% today, with a bearish technical signal from moving averages and an overbought RSI. The company reported revenue of $56.67B in 2025, with a net income margin of 22.5%, and recently announced a $7.8B licensing deal with China's Abogen for RNA-based therapy. Earnings have been mixed, beating in Q4 2025 and Q2 2026 but missing in Q1 2026.
The outlook is cautious due to recent clinical trial setbacks and investor scrutiny of M&A strategy. Analyst consensus is a $146 price target with a hold-heavy rating. Risks include pipeline failures and competitive pressures, but strong cash flow and profitability provide support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
